- •Polypharmacy in this alemtuzumab-exposed MS cohort was common.
- •Several of the medication classes initiated with alemtuzumab did not include drugs recommended to minimize or prevent adverse drug reactions.
- •A substantial drug burden was observed both before and after initiating alemtuzumab.
Medications are indicated to minimize adverse reactions with alemtuzumab treatment for multiple sclerosis, but polypharmacy can be problematic. We characterized prescriptions filled by 160 individuals before, during and after first infusion of alemtuzumab (Dec/2013-Jun/2017). Ninety-five percent of individuals filled ≥1 prescription(s) before alemtuzumab across 87 unique drug classes, averaging 5.3 prescriptions/person over 47 weeks. During the infusion period, 90% filled ≥1 prescription(s) for 40 new drug classes, averaging 2.2 prescriptions/person over 5 weeks. Twenty-four percent refilled ≥1 of these prescription(s) after alemtuzumab across 17 drug classes, averaging 0.3 refills/person over 24 weeks. There was substantial medication burden throughout the study.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Multiple Sclerosis and Related Disorders
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Polypharmacy in outpatients with relapsing-remitting multiple sclerosis: a single-center study.PLoS ONE. 2019; 14e0211120
- Multi-drug use among patients with multiple sclerosis: a cross-sectional study of associations to clinicodemographic factors.Sci. Rep. 2019; 6: 3743
- Routine deprescribing of chronic medications to combat polypharmacy.Ther. Adv. Drug Saf. 2015; 6: 212-233
- Costs of illness of multiple sclerosis in Sweden: a population-based register study of people of working age.Eur. J. Health Econ. 2018; 19: 435-446
- Polypharmacy: evaluating risks and deprescribing.Am. Fam. Physic. 2019; 100: 32-38
Health Canada. Product monograph including patient medication information. Lemtrada® (alemtuzumab 12 mg/1.2 mL). Concentrate for solution for intravenous infusion. Therapeutic Classification: Selective Immunomodulator. 2019 [Sept 2019]. Available from: https://pdf.hres.ca/dpd_pm/00051184.PDF.
- Medication use in a large international sample of people with multiple sclerosis: associations with quality of life, relapse rate and disability.Neurol. Res. 2015; 37: 662-673
- Overcoming inertia to improve medication use and deprescribing.JAMA. 2018; 13: 1867-1869
Published online: April 27, 2020
Accepted: March 31, 2020
Received: March 30, 2020
© 2020 Elsevier B.V. All rights reserved.